OptiNose Inc OPTN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 1:11 PM EDT
1.25quote price arrow down-0.04 (-3.10%)
Volume
519,222
52 week range
0.80 - 2.10
Loading...
  • Open1.30
  • Day High1.33
  • Day Low1.23
  • Prev Close1.29
  • 52 Week High2.10
  • 52 Week High Date03/18/24
  • 52 Week Low0.80
  • 52 Week Low Date04/26/24

Key Stats

  • Market Cap181.048M
  • Shares Out144.84M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-0.07
  • YTD % Change-3.49

KEY STATS

  • Open1.30
  • Day High1.33
  • Day Low1.23
  • Prev Close1.29
  • 52 Week High2.10
  • 52 Week High Date03/18/24
  • 52 Week Low0.80
  • 52 Week Low Date04/26/24
  • Market Cap181.048M
  • Shares Out144.84M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-0.07
  • YTD % Change-3.49

RATIOS/PROFITABILITY

  • EPS (TTM)-0.27
  • P/E (TTM)-4.57
  • Fwd P/E (NTM)-5.04
  • EBITDA (TTM)-16.041M
  • ROE (TTM)-1,050.50%
  • Revenue (TTM)74.022M
  • Gross Margin (TTM)88.98%
  • Net Margin (TTM)-41.47%
  • Debt To Equity (MRQ)-131.69%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On OptiNose Inc

 

Profile

MORE
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE...
R. John Fletcher
Independent Chairman of the Board
Ramy Mahmoud M.D.
Chief Executive Officer, Director
Anthony Krick
Chief Accounting Officer
Address
1020 Stony Hill Rd Ste 300
Yardley, PA
19067-5539
United States

Top Peers

SYMBOLLASTCHG%CHG
ALIM
Alimera Sciences Inc
3.27-0.01-0.30%
CDXC
Chromadex Corp
3.41-0.07-2.01%
MDWD
Mediwound Ltd
17.32+0.03+0.17%
SCPH
scPharmaceuticals Inc
4.75-0.08-1.55%
AQST
Aquestive Therapeutics Inc
3.18-0.10-3.05%